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In this issue, Philippe Kern
1 describes a method
for treating leg telangiectasia. The aim of this
study was to investigate a possible method for pain
reduction. Leg telangiectasias are a common
problem in dermatologic surgical practice. Because
of a lack of randomized controlled trials, most
literature reports are restricted to a personal
approach.2,3 From dermato-phlebologic3 and
cosmetic4 points of view, sclerotherapy is regarded
as the first treatment option. There is much discus-
sion about the place of lasers,5 but treatment of leg
telangiectasias is a challenge. Side effects such as
hyperpigmentation and small but resistant ulcers
are more frequent than perhaps reported. In
addition, treatment failures and recurrences are not
uncommon.
It is a clinical observation that retreatment for
recurrences becomes more difficult than the initial
treatment. Kern has chosen an adequate approach
to the treatment problem. He proposes first to treat
the feeder reticular vein. For this he compared two
techniques. The first technique is an injection at
the most distal aspect of the feeder vein and, in a
subsequent visit, an injection in the remaining
telangiectasia, and the second technique is an
injection in each side branch of the feeding
reticular vein and telangiectasia at the same time.
The effectiveness is the same, but pain is
significantly less using the two-step method.
Unfortunately, he uses chromated glycerin as a
sclerosing solution. This sclerosant is mainly
used in France and some parts of Switzerland.
Sclerotherapy pain sensation is different for each
sclerosing agent. Hypertonic saline is the most
painful and polidocanol the least painful.
Chromated glycerin is said to cause more pain
than polidocanol, so translation of this technique
to extensive use of polidocanol is impossible. The
use of epinephrine, added to the chromated glyc-
erin, seems to be confounding. It will induce vaso-
spasm, although the author did not observe
vasospasm.
The most interesting aspect of the two-step
treatment that the author proposes is the large
number of injections. There is no significant
difference between the techniques in numbers of
injection. Because the amount of sclerosing
solution injected should be just enough to fill
the target vein, the volume per injection is
automatically reduced with the number of
injections per area. Pain reduction for a mostly
cosmetic treatment will increase patient
satisfaction, which measured the authors
did not measure. It will be of great interest to
compare the low-volume/high-injection technique
with the approach in which the injected volume
is based on the maximum filling of a certain
vessel.2,3
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